p47/gp91 gene therapy - Nexell Therapeutics

Drug Profile

p47/gp91 gene therapy - Nexell Therapeutics

Latest Information Update: 06 Aug 2003

Price : $50

At a glance

  • Originator Nexell Therapeutics [CEASED]
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological disorders

Most Recent Events

  • 30 Dec 2002 Discontinued - Phase-III for Haematological disorders in USA (Parenteral)
  • 15 May 2002 Nexell Therapeutics has announced the winding down of company operations
  • 07 Nov 2001 Phase-III clinical trials for Haematological disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top